|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002199,
umls-concept:C0008838,
umls-concept:C0013089,
umls-concept:C0013216,
umls-concept:C0016360,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0205195,
umls-concept:C0332293,
umls-concept:C0871261,
umls-concept:C1519810,
umls-concept:C1521761,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2239176,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-3-19
|
|
pubmed:abstractText |
The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy consisting of cisplatin, alpha-interferon, doxorubicin, and 5-fluorouracil (PIAF).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
421-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11905412-Adolescent,
pubmed-meshheading:11905412-Adult,
pubmed-meshheading:11905412-Aged,
pubmed-meshheading:11905412-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11905412-Bilirubin,
pubmed-meshheading:11905412-Carcinoma, Hepatocellular,
pubmed-meshheading:11905412-Child,
pubmed-meshheading:11905412-Cisplatin,
pubmed-meshheading:11905412-Doxorubicin,
pubmed-meshheading:11905412-Drug Administration Schedule,
pubmed-meshheading:11905412-Female,
pubmed-meshheading:11905412-Fluorouracil,
pubmed-meshheading:11905412-Humans,
pubmed-meshheading:11905412-Interferon-alpha,
pubmed-meshheading:11905412-Liver Cirrhosis,
pubmed-meshheading:11905412-Liver Neoplasms,
pubmed-meshheading:11905412-Male,
pubmed-meshheading:11905412-Middle Aged,
pubmed-meshheading:11905412-Neoplasm Staging,
pubmed-meshheading:11905412-Recombinant Proteins,
pubmed-meshheading:11905412-Remission Induction,
pubmed-meshheading:11905412-Risk Factors,
pubmed-meshheading:11905412-Survival Rate,
pubmed-meshheading:11905412-Time Factors,
pubmed-meshheading:11905412-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
|
|
pubmed:affiliation |
Department of Clinical Oncology, The Chinese University of Hong Kong, SAR. waitongleung@cuhk.edu.hk
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
